CAMBRIDGE, Mass., Oct. 1, 2018 /PRNewswire/ -- BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced its participation in the Cell & Gene Meeting on the Mesa, to be held Oct. 3-5 in La Jolla, Calif.
Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock, and Robert Deans, Ph.D., Chief Technology Officer of BlueRock, will be speaking at the conference. BlueRock's novel Cell+Gene platform is designed to develop, manufacture and deliver native cell therapies with high purity, potency and specificity. BlueRock can further enhance these native cells by engineering added capability and function to pursue new medicines across both rare and more prevalent chronic diseases.
The following are specific details regarding BlueRock's participation at the conference:
Event: Successful Strategies in the Design and Delivery of a Cell/Gene Therapy Clinical Development Program Workshop; Session 1: U.S.-based Clinical Programs
Type: Interactive Panel with Dr. Robert Deans
Date: Oct. 3
Time: 7:20a.m.-8:00a.m.
Location: Ballroom 2 at the Estancia La Jolla Hotel & Spa
Event: BlueRock Therapeutics Company Presentation
Type: Corporate Presentation by Dr. Emile Nuwaysir
Date: Oct. 3
Time: 11:45a.m.-12:00p.m.
Location: Ballroom 2 at the Estancia La Jolla Hotel & Spa
Event: Gala Reception
Type: Reception sponsored by BlueRock Therapeutics and CCRM
Date: Oct. 3
Time: 6:30p.m.-9:30p.m.
Location: Garden Courtyard at the Estancia La Jolla Hotel & Spa
A live video webcast of all company presentations and workshops will be available at: http://www.meetingonthemesa.com/webcast/ and will also be published on the conference website shortly after the event.
This conference is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing the opportunity for participants to establish key relationships and accelerate business development. Organized by the Alliance for Regenerative Medicine and the Sanford Stem Cell Clinical Center at the University of California-San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The event's Partnering Forum on October 3rd-4th features more than 70 dedicated company presentations in addition to over 90 panelists and featured speakers.
About BlueRock Therapeutics
BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock's Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock's culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.
Media Contacts:
David Schull or Maggie Beller
Russo Partners, LLC
(646) 942-5631
Maggie.beller@russopartnersllc.com
SOURCE BlueRock Therapeutics
